According to the packet definition, most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion. The packet's inheritance field lists a multifactorial pattern. A gene association appears in the packet without a certified validity level, so no gene-specific claims are made here. The packet lists subtypes including bone chondrosarcoma, mesenchymal chondrosarcoma, localized chondrosarcoma, and myxoid chondrosarcoma, and Orphanet-derived data place the condition in the uncommon category, at 1 to 9 per 100,000 people.

Diagnostic methods and criteria are not certified in this packet.

Treatment information is not certified in this packet, and no FDA-approved treatment is listed. The packet lists two orphan drug designations for the treatment of chondrosarcoma. An orphan designation does not indicate approval, efficacy, or active development.

Prognosis is not certified in this packet.

ClinicalTrials.gov records in the packet that name chondrosarcoma include the following, listed by registry title; a title does not establish what an intervention achieves. NCT00496522 is a Phase 2 study of proton beam therapy for chondrosarcoma (M.D. Anderson Cancer Center; active, not recruiting). NCT04340843 is a Phase 2 National Cancer Institute study in unresectable and metastatic conventional chondrosarcoma (active, not recruiting). NCT01267955 is a Phase 2 National Cancer Institute study in patients with advanced chondrosarcomas (active, not recruiting). NCT04458922 is a Phase 2 National Cancer Institute study in people 2 to 17 years old with clear cell sarcoma or advanced chondrosarcoma (active, not recruiting). NCT04950075 is a Phase 2 study in conventional chondrosarcoma (Inhibrx Biosciences; active, not recruiting). Active clinical trials for this condition are listed on ClinicalTrials.gov.